Texas Attorney General Ken Paxton has launched a probe into two pharmaceutical companies that allegedly advertised and promoted puberty-blocking drugs to minors who suffer from gender dysphoria.
The medications in question include Supprelin LA and Lupron Depot, which are federally approved to treat children with Central Precocious Puberty (CPP), or premature puberty. Another drug, Vantas, has been prescribed for palliative therapy for advanced prostate cancer. The U.S. Food and Drug Administration has not approved any of these drugs as treatments for gender dysphoria.
